Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.
Actively Recruiting
Researchers are evaluating the use of SNP-ACTH 1-39 Gel compared to rituximab for treating adults with primary membranous nephropathy PMN, a kidney condition. This trial uses a two-phase adaptive design to find the best dose of SNP-ACTH Gel and then assess its effectiveness against rituximab. The study is divided into Phase 3a for dose finding and Phase 3b for comparing treatments over 24 months. In Phase 3a, up to 24 patients will be randomly assigned to receive either 3 mg or 5 mg of SNP-ACTH Gel by subcutaneous injection three times a week for 12 months. Data from this phase will guide dose selection for Phase 3b. In Phase 3b, 132 patients will be randomized to receive either the selected dose of SNP-ACTH Gel for 12 months or rituximab infusions given in two cycles, one at the start and one at six months. Participants will be monitored throughout the study with regular assessments of urinary protein and auto-antibody levels during Phase 3a, and clinical responses at 24 months in Phase 3b. Researchers will track kidney function, relapse rates, immune responses, and safety outcomes. Study visits and evaluations will occur at multiple time points up to two years, supporting detailed understanding of treatment effects and patient health over time.
Actively Recruiting
Researchers are evaluating centhaquine citrate LYFAQUIN1, a novel drug being studied as a resuscitative agent for adults with hypovolemic shock, which is a life-threatening condition caused by severe blood or fluid loss. This phase IV, open-label, multi-center study aims to assess the safety and efficacy of centhaquine when added to the standard shock treatment. Centhaquine acts on specific receptors to improve blood flow and reduce vascular resistance, with prior studies showing promising effects on blood pressure, lactate levels, cardiac output, and mortality in animal models. Participants aged 18 years or older with hypovolemic shock and low systolic blood pressure 90 mmHg or lower will receive centhaquine intravenously at a dose of 0.01 mgkg body weight over one hour, in addition to standard care such as fluid resuscitation and vasopressors. A second dose may be given if blood pressure remains low, with no more than three doses in 24 hours and treatment continuing up to two days after enrollment. Each patient will receive between one and six doses within the first 48 hours. Throughout hospitalization, participants will be monitored closely until discharge or up to seven days after joining the trial. Researchers will assess safety by tracking adverse events and efficacy by measuring blood pressure, lactate levels, base deficit, ICU stay duration, ventilator use, urine output, mortality, organ dysfunction scores, respiratory distress, and neurological status. Statistical analyses will compare patient outcomes to understand centhaquines effects as an addition to standard hypovolemic shock treatment.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are evaluating the use of antiplatelet therapy, specifically Aspirin 75 mg daily, to prevent major adverse cardiovascular and cerebrovascular events MACE in patients who have survived intracerebral haemorrhage ICH. This Phase 3, randomized, placebo-controlled, triple-blinded clinical trial plans to recruit 5676 patients aged 18 to 99 years across 50 stroke centers in India. The study aims to address the safety and effectiveness of starting antiplatelet monotherapy after ICH, a question not yet resolved by large trials. Participants will be randomly assigned to receive either daily Aspirin 75 mg or a matching placebo, both alongside standard secondary prevention care. The medication and follow-up duration depend on recruitment timing those recruited in the first year will take the medication for up to three years or until an event occurs, while those recruited later will take it for a minimum of six months with matching follow-up. The total trial duration is three years, with recruitment lasting 2.5 years and follow-up continuing until the study ends. The investigational products are centrally manufactured and dispensed yearly at each site. Participants will undergo face-to-face visits every three months to receive the medication and return unused tablets, with monthly phone calls to monitor adherence and detect any events. Brain imaging by CT or MRI will be done as part of routine care at baseline and if events occur. Researchers will collect clinical data, medication adherence, and functional assessments such as the modified Rankin Scale. Safety monitoring includes event adjudication and follow-up until three years or until withdrawal, death, or event occurrence. The primary outcome is the occurrence of MACE over three years.